The work Hypnosis and Oncological Pathologies explores the potential of clinical hypnosis as an integrated tool within cancer therapy, with a particular focus on its immunomodulatory effects documented in scientific literature. Within the model of integrative oncology—which combines conventional treatments with evidence-based complementary interventions—hypnosis emerges as a method capable of influencing the psychoneuroimmunological mechanisms underlying the body's response to cancer.


Research findings (Zachariae et al., 1991; Ruzyla-Smith et al., 1995; Gruzelier et al., 2002; Spiegel et al., 2007; Banyai & Varga, 2012) demonstrate that hypnotic induction can increase NK cell and T-helper activity, reduce cortisol levels, and enhance the production of immunoglobulin A (IgA), thus promoting a more efficient immune regulation. These effects are mediated by the reduction of psychological stress and the restoration of neuroendocrine balance—key elements in the mind-body connection.


The Ericksonian approach, centered on rapport, indirect communication, and therapeutic tailoring, encourages the patient's active involvement in the healing process, transforming hypnotic suggestion into a physiological stimulus for cellular self-regulation. Hypnotic visualizations—aimed at perceiving immune cells as "allies" in the body's defense—show a significant impact on psychological well-being, sleep quality, pain management, and overall quality of life in cancer patients.


Particular emphasis is placed on the contributions of Eva Bányai, who integrates clinical evidence and personal experience, highlighting the ethical responsibility of professionals to convey positive and conscious suggestions in contexts of vulnerability. Hypnosis, conceived as a dynamic interface between the mind and the immune system, thus emerges as a powerful psychobiological tool capable of enhancing the efficacy of oncological treatments and fostering the patient's integrated resilience.